Shang Hai Zheng Quan Bao·2026-02-11 18:41Group 1: Board Election Announcement - The company announced the election of Mr. Zhao Yong as the employee representative director of the eighth board of directors, following the approval of the employee representative conference held on February 11, 2026 [1][3] - Mr. Zhao Yong meets the qualifications and conditions for the position as stipulated by relevant laws and the company's articles of association [1] - The number of directors who are also senior management and those who are employee representatives does not exceed half of the total number of directors, complying with legal requirements [1] Group 2: Stock Option Incentive Plan - The company reported that 680,000 stock options from the third exercise period of the 2019 A-share stock option incentive plan were available for exercise from February 8, 2025, to February 7, 2026 [5] - No stock options were exercised during the third exercise period, and the unexercised options will be canceled by the company [6][17] - The total share capital of the company as of the end of the third exercise period was 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status [22] Group 3: Approval of Raw Material Drug - The company announced that its subsidiary, Shanghai Pharmaceutical Kangli, received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride [23][24] - Tamsulosin hydrochloride is a third-generation selective long-acting α1 blocker used for treating benign prostatic hyperplasia (BPH) [25] - The company has invested approximately RMB 1.5 million in research and development for this drug, which is expected to enhance its market presence [26]